Sector News

Sanofi sacks chief executive Viehbacher

October 29, 2014
Life sciences
Sanofi’s Board of Directors has sacked chief executive Chris Viehbacher abruptly cutting his six-year run at the helm of the firm.
 
The French drugmaker said in a rather terse statement this morning that the Board had “unanimously” agreed to “remove” Viebacher, but also thanked him for “all the work done during the last six years, which has enabled the Group to move through a sensitive and important transition phase”. 
 
The rumour mill has been running for some time over Viehbacher’s future at the firm, largely because of his tough management style, relocation to the US this year, and recent run in with chairman Serge Weinberg. French newspaper Les Echos published last week a letter dated September 4 in which Viehbacher said he had become aware that Weinberg was “actively seeking a successor”.
 
“Changing the CEO would be against a backdrop of a company and a leader perceived to be succeeding strongly. Such a change would be difficult to understand”, he wrote, making his case to stay in the role.
 
Disagreement and poor cooperation
Weinberg reportedly said the decision to sack him was made because of disagreement over the chief executive’s management style and poor cooperation with the board, according to Reuters, and he also told a press conference that there was “a lack of trust in Viehbacher’s relationship with the board”.
 
In a statement, the Board said Sanofi “needs to pursue its development with a management aligning the teams, harnessing talents and focusing on execution with a close and confident cooperation with the board”.
 
None-the-less, it is quite shocking that the firm made the move without having a replacement lined up. For now, Weinberg will assume the role temporarily.
 
The news, coupled with yesterday’s that diabetes sales at the firm could be flat next year, saw almost 17 billion euros wiped from its value this week, according to reports.
 
By Selina McKee
 
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach